Lenvatinib Mesylate
Brand name: Lenvima
Rank #111 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$164.6M
Total Cost
7,004
Total Claims
$164.6M
Total Cost
387
Prescribers
$24K
Cost per Claim
130
Beneficiaries
7,080
30-Day Fills
$425K
Avg Cost/Provider
18
Avg Claims/Provider
Share of Medicare Part D Spending
0.06%
of total Medicare Part D spending
$164.6M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $164.6M total
🔎 Data Overview
At $23,502 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $425,343 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $1,266,214 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Lenvatinib Mesylate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Marcia Brose | Medical Oncology | Philadelphia, PA | 173 | $4.2M |
| 2 | David Hsieh | Medical Oncology | Dallas, TX | 74 | $1.9M |
| 3 | Sunyoung Lee | Medical Oncology | Houston, TX | 66 | $1.6M |
| 4 | Robert Alter | Hematology-Oncology | Hackensack, NJ | 67 | $1.5M |
| 5 | Kevin Becker | Hematology-Oncology | New York, NY | 56 | $1.4M |
| 6 | Yiqing Xu | Hematology-Oncology | Brooklyn, NY | 53 | $1.3M |
| 7 | Edmund Folefac | Medical Oncology | Columbus, OH | 63 | $1.3M |
| 8 | Kenneth Ain | Endocrinology | Lexington, KY | 61 | $1.3M |
| 9 | Hari Deshpande | Medical Oncology | New Haven, CT | 49 | $1.2M |
| 10 | Jennifer Hernandez | Physician Assistant | New Hyde Park, NY | 52 | $1.2M |
| 11 | Tarenne Carrington | Nurse Practitioner | Philadelphia, PA | 46 | $1.1M |
| 12 | Yokasta Garcia | Physician Assistant | Bronx, NY | 45 | $1.1M |
| 13 | Neil Shah | Hematology-Oncology | Washington, DC | 46 | $1.1M |
| 14 | Emily Feld | Hematology-Oncology | Philadelphia, PA | 49 | $1.0M |
| 15 | Brian Rini | Hematology-Oncology | Nashville, TN | 39 | $976K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 108 | Lifitegrast (Xiidra) | $166.6M | 149,269 |
| 109 | Alirocumab (Praluent Pen) | $165.6M | 203,805 |
| 110 | Pantoprazole Sodium (Pantoprazole Sodium) | $165.1M | 10,061,854 |
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
| 113 | Rimegepant Sulfate (Nurtec Odt) | $155.0M | 106,692 |
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology